Coherus Oncology (CHRS) Return on Invested Capital (2019 - 2023)

Coherus Oncology has disclosed Return on Invested Capital across 4 years of filings, most recently posting 0.01% for Q4 2023.

• Return on Invested Capital for Q4 2023 came in at 0.01%, changed N/A year-over-year; the trailing twelve-month figure through Dec 2023 was 0.01% (changed N/A YoY), and the FY2023 annual result was 0.01%, changed N/A from the prior year.
• Return on Invested Capital came in at 0.01% for Q4 2023 at Coherus Oncology, up from 0.01% in the prior quarter.
• In the past five years, Return on Invested Capital ranged from a high of 0.01% in Q4 2023 to a low of 0.01% in Q2 2019.
• The 4-year median for Return on Invested Capital is 0.0% (2020), against an average of 0.0%.
• Peak annual rise in Return on Invested Capital reached 2 bps in 2020, while the deepest fall reached 1 bps in 2020.
• Coherus Oncology's Return on Invested Capital stood at 0.01% in 2019, then sank by 58 bps to 0.0% in 2020, then sank by 292 bps to 0.01% in 2021, then surged by 240 bps to 0.01% in 2023.
• The last three Return on Invested Capital figures came in at 0.01% (Q4 2023), 0.01% (Q3 2023), and 0.01% (Q3 2021), per Business Quant data.